Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average PT from Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has earned a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $17.25.

Several research firms recently weighed in on ENTA. HC Wainwright cut their price target on shares of Enanta Pharmaceuticals from $27.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, December 24th. Robert W. Baird cut their target price on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 26th. Finally, JMP Securities reiterated a “market outperform” rating and set a $21.00 price target (down previously from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 26th.

Insider Activity

In related news, CEO Jay R. Luly sold 5,142 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.06, for a total value of $41,444.52. Following the sale, the chief executive officer now owns 801,638 shares in the company, valued at $6,461,202.28. This represents a 0.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 13.64% of the company’s stock.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in ENTA. Allspring Global Investments Holdings LLC purchased a new position in shares of Enanta Pharmaceuticals in the 2nd quarter worth about $35,000. US Bancorp DE lifted its stake in shares of Enanta Pharmaceuticals by 4,933.7% in the third quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock worth $45,000 after buying an additional 4,243 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Enanta Pharmaceuticals during the third quarter valued at approximately $122,000. Quest Partners LLC increased its position in shares of Enanta Pharmaceuticals by 511.2% during the second quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $150,000 after acquiring an additional 9,692 shares in the last quarter. Finally, Valence8 US LP purchased a new position in Enanta Pharmaceuticals in the 3rd quarter worth approximately $207,000. 94.99% of the stock is owned by institutional investors.

Enanta Pharmaceuticals Trading Up 0.2 %

Enanta Pharmaceuticals stock opened at $6.01 on Thursday. The firm has a market cap of $127.38 million, a P/E ratio of -1.10 and a beta of 0.49. Enanta Pharmaceuticals has a 1-year low of $5.70 and a 1-year high of $17.80. The firm has a 50-day moving average of $9.15 and a 200-day moving average of $11.47.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, November 25th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.20). Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. The business had revenue of $14.60 million for the quarter, compared to the consensus estimate of $17.99 million. During the same period in the previous year, the company earned ($1.33) EPS. The company’s revenue for the quarter was down 22.8% on a year-over-year basis. Research analysts forecast that Enanta Pharmaceuticals will post -4.73 earnings per share for the current fiscal year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.